PL EN


Preferences help
enabled [disable] Abstract
Number of results
2013 | 67 | 1 | 61–66
Article title

Potencjalne znaczenie diagnostyczne lipokaliny neutrofilowej związanej z żelatynazą

Content
Title variants
EN
Potential diagnostic significance of neutrophil gelatinase-associated lipocalin
Languages of publication
PL
Abstracts
EN
Neutrophil gelatinase-associated lipocalin (NGAL) has been the subject of studies in various medical fields. It belongs to extracellular proteins, is secreted by such cells as respiratory and intestinal epithelial cells, cells of the immune system and tubuli cells in the kidneys. NGAL is engaged in acute and chronic inflammatory processes and oncogenesis. It is a candidate to become the new marker of kidney injury, however, based on numerous studies in different medical areas like surgery, oncology or diabetology the diagnostic and also prognostic significance of NGAL may include more than only kidney disorders.
PL
Rola lipokaliny neutrofilowej związanej z żelatynazą (neutrophil gelatinase-associated lipocalin – NGAL) stanowi przedmiot badań w wielu dziedzinach medycyny. Jest to białko zewnątrzkomórkowe wydzielane przez komórki przewodu pokarmowego, układu oddechowego, komórki cewek nerkowych oraz układu immunologicznego. Bierze udział w ostrych i przewlekłych procesach zapalnych oraz onkogenezie. Zyskało w nefrologii pozycję kandydata na „nowy” marker uszkodzenia nerek. Na podstawie doniesień naukowych z innych dziedzin, jak: chirurgia, onkologia czy diabetologia można stwierdzić, że przydatność diagnostyczna, a także rokownicza tego białka może potencjalnie obejmować wiele jednostek chorobowych.
Discipline
Publisher

Year
Volume
67
Issue
1
Pages
61–66
Physical description
Contributors
  • Katedra i Oddział Kliniczny Pediatrii Wydziału Nauk o Zdrowiu Śląskiego Uniwersytetu Medycznego w Katowicach
  • Katedra i Oddział Kliniczny Pediatrii Wydziału Nauk o Zdrowiu Śląskiego Uniwersytetu Medycznego w Katowicach ul. Batorego 15 41-902 Bytom tel. +48 32 786 14 98, pedbyt@sum.edu.pl
References
  • 1. Flower D.R. The lipocalin protein family: structure and function. Biochem. J. 1996; 318: 1–14.
  • 2. Tong Z., Wu X., Ovcharenko D., Zhu J., Chen C.S., Kehrer J.P. Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem. J. 2005; 391: 441–448.
  • 3. Kjeldsen L., Johnsen AH., Sengeløv H., Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 1993; 268: 10425–10432.
  • 4. Schmidt-Ott KM., Mori K., Li JY. i wsp. Dual action of neutrophil gelatinase-associated lipocalin. J. Am. Soc. Nephrol. 2007; 18: 407–413.
  • 5. Schmidt-Ott K.M. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury – where do we stand today? Nephrol. Dial. Transplant. 2011; 26: 762–764.
  • 6. Yang Y.H., He X.J., Chen S.R., Wang L., Li E.M., Xu L.Y. Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study. Endocrine 2009; 36: 45–51.
  • 7. Mitsnefes M.M., Kathman T.S., Mishra J. i wsp. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr. Nephrol. 2007; 22: 101–108.
  • 8. Mussap M., Noto A., Fravega M., Fanos V. Urine neutrophil gelatinase-associated lipocalin (uNGAL) and netrin-1: are they effectively improving the clinical management of sepsis-induced acute kidney injury (AKI)? J. Matern. Fetal Neonatal. Med. 2011; Suppl 2: 15–17.
  • 9. Bataille A., Abbas S., Semoun O. i wsp. Plasma neutrophil gelatinase-associated lipocalin in kidney transplantation and early renal function prediction. Transplantation 2011; 92: 1024–1030.
  • 10. Wheeler D.S., Devarajan P., Ma Q. i wsp. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Crit. Care Med. 2008; 36: 1297–1303.
  • 11. Haase M., Bellomo R., Devarajan P., Schlattmann P., Haase-Fielitz A. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009; 54: 1012–1024.
  • 12. Hirsch R., Dent C., Pfriem H. i wsp. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr. Nephrol. 2007; 22: 2089–2095.
  • 13. Gaspari F., Cravedi P., Mandalà M. i wsp. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. Nephron Clin. Pract. 2010; 115: c154–c160.
  • 14. Mishra J., Mori K., Ma Q. i wsp. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J. Am. Soc. Nephrol. 2004; 15: 3073–3082.
  • 15. Wasilewska A., Taranta-Janusz K., Dębek W., Zoch-Zwierz W., Kuroczycka-Saniutycz E. KIM-1 and NGAL: new markers of obstructive nephropathy. Pediatr. Nephrol. 2011; 26: 579–586.
  • 16. Ding H., He Y., Li K. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin. Immunol. 2007; 123: 227–234.
  • 17. Blumczynski A., Sołtysiak J., Lipkowska K. i wsp. Hypertensive nephropathy in children – do we diagnose early enough? Blood Press 2012; 21: 233–239.
  • 18. Hinze C.H., Suzuki M., Klein-Gitelman M. i wsp. Neutrophil gelatinase-associated lipocalin anticipates the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum. 2009; 60: 2772–2781.
  • 19. Devarajan P. Emerging biomarkers of acute kidney injury. Contrib. Nephrol. 2007; 156: 203–212.
  • 20. Bourgeois E., Bataille A., Jacob L. Perioperative modifications in kidney function. Presse Med. 2009; 38: 1621–1629.
  • 21. Cai L., Borowiec J., Xu S., Han W., Venge P. Assays of urine levels of HNL/NGAL in patients undergoing cardiac surgery and the impact of antibody configuration on their clinical performances. Clin. Chim. Acta 2009; 403: 121–125.
  • 22. Malyszko J., Bachorzewska-Gajewska H., Poniatowski B., Malyszko J.S., Dobrzycki S. Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease. Ren. Fail. 2009; 31: 910–919.
  • 23. Malyszko J., Bachorzewska-Gajewska H., Malyszko J.S., Pawlak K., Dobrzycki S. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease. Nephrology 2008; 13: 153–156.
  • 24. Leoncini G., Mussap M., Viazzi F. i wsp. Combined use of urinary neutrophil gelatinase-associated lipocalin (uNGAL) and albumin as markers of early cardiac damage in primary hypertension. Clin. Chim. Acta. 2011; 412: 1951–1956.
  • 25. Bolignano D., Coppolino G., Lacquaniti A., Buemi M. From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. Eur. J. Clin. Invest. 2010; 40: 273–276.
  • 26. Hawkins R. New biomarkers of acute kidney injury and the cardio-renal syndrome. Korean J. Lab. Med. 2011; 31: 72–80.
  • 27. Aghel A., Shrestha K., Mullens W., Borowski A., Tang W.H. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J. Card. Fail. 2010; 16: 49–54.
  • 28. Alvelos M., Lourenço P., Dias C. i wsp. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int. J. Cardiol. 2011 Aug 26.
  • 29. Thrailkill K.M., Moreau C.S., Cockrell G.E. i wsp. Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus; Endocrine 2010; 37: 336–343.
  • 30. Bolignano D., Lacquaniti A., Coppolino G. i wsp. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res. 2009; 32: 91–98.
  • 31. Bolignano D., Donato V., Lacquaniti A. i wsp. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett 2010; 288: 10–16.
  • 32. Wang L., Li H., Wang J. i wsp. C/EBP ζ targets to neutrophil gelatinase-associated lipocalin (NGAL) as a repressor for metastasis of MDA-MB-231 cells. Biochim. Biophys. Acta. 2011; 1813: 1803–1813.
  • 33. Leng X., Lin H., Ding T. i wsp. Lipocalin 2 is required for BCR-ABLinduced tumorigenesis. Oncogene 2008; 27: 6110–6119.
  • 34. Leng X., Ding T., Lin H. i wsp. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res. 2009; 69: 8579–8584.
  • 35. Tong Z., Kunnumakkara AB., Wang H. i wsp. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 2008; 68: 6100–6108.
  • 36. Du ZP., Lv Z., Wu BL. i wsp. Neutrophil gelatinase-associated lipocalin and its receptor: independent prognostic factors of oesophageal squamous cell carcinoma. J. Clin. Pathol. 2011; 64: 69–74.
  • 37. Wang H.J., He X.J., Ma Y.Y. i wsp. Expressions of neutrophil gelatinase-associated lipocalin in gastric cancer: a potential biomarker for prognosis and an ancillary diagnostic test. Anat. Rec. 2010; 293: 1855–1863.
  • 38. Barresi V., Tuccari G., Barresi G. NGAL immunohistochemical expression in brain primary and metastatic tumors. Clin. Neuropathol. 2010; 29: 317–322.
  • 39. Oikonomou K.A., Kapsoritakis A.N., Theodoridou C. i wsp. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J. Gastroenterol. 2012; 47: 519–530.
  • 40. Bousserouel S., Kauntz H., Gossé F. i wsp. Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis. Int. J. Oncol. 2010; 36: 1485–1490.
  • 41. Cernaro V., Bolignano D., Donato V. i wsp. NGAL is a precocious marker of therapeutic response. Curr. Pharm. Des. 2011; 17: 844–849.
  • 42. Chakraborty S., Kaur S., Muddana V. i wsp. Elevated serum neutrophil gelatinase-associated lipocalin is an early predictor of severity and outcome in acute pancreatitis. Am. J. Gastroenterol. 2010; 105: 2050–2059.
  • 43. Manfredi M.A., Zurakowski D., Rufo P.A., Walker T.R., Fox V.L., Moses M.A. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2008; 14: 1091–1096.
  • 44. Eagan T.M., Damås J.K., Ueland T. i wsp. Neutrophil gelatinase-associated lipocalin: a biomarker in COPD. Chest 2010; 138: 888–895.
  • 45. Smith E.R., Zurakowski D., Saad A., Scott RM., Moses M.A. Urinary biomarkers predict brain tumor presence and response to therapy. Clin. Cancer Res. 2008; 14: 2378–2386.
  • 46. McKittrick I.B., Bogaert Y., Nadeau K. i wsp. Urinary matrix metalloproteinase activities: biomarkers for plaque angiogenesis and nephropathy in diabetes. Am. J. Physiol. Renal Physiol. 2011; 301: 326–333.
  • 47. Zachwieja J., Soltysiak J., Fichna P. i wsp. Normal-range albuminuria does not exclude nephropathy in diabetic children. Pediatr. Nephrol. 2010; 25: 1445–1451.
  • 48. Yilmaz A., Sevketoglu E., Gedikbasi A. i wsp. Early prediction of urinary tract infection with urinary neutrophil gelatinase-associated lipocalin. Pediatr. Nephrol. 2009; 24: 2387–2392.
  • 49. Biezeveld M.H., van Mierlo G., Lutter R. i wsp. Sustained activation of neutrophils in the course of Kawasaki disease: an association with matrix metalloproteinases. Clin. Exp. Immunol. 2005; 141: 183–188.
  • 50. Capoluongo E., Vento G., Lulli P. i wsp. Epithelial lining fluid neutrophil-gelatinase-associated lipocalin levels in premature newborns with bronchopulmonary dysplasia and patency of ductus arteriosus. Int. J. Immunopathol. Pharmacol. 2008; 21: 173–179.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-349f5085-db88-4e88-a5fe-7a085c5f04e2
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.